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Acute HIV and acute hepatitis B coinfection is extremely rare. A 23-year-old homosexual man was admitted to our hospital with
5-day history of fever, malaise, and back pain with initial laboratory values showing severe transaminitis. The clinical picture
was initially suggestive of acute viral hepatitis, which on further testing revealed acute hepatitis B and acute HIV coinfection.
Although the patient was asymptomatic, a decision was made to start antiretroviral therapy. At 2-month followup, liver function
tests were normal with undetectable viral loads. The early treatment of acute HIV/HBV coinfections likely contributed to eventual
seroconversion with immunity to HBV in a severely immunocompromised host. To the best of our knowledge, this is the ﬁrst case
report of acute Hepatitis B and acute HIV coinfection and its management. In conclusion, early treatment of acute hepatitis B in
immunocompromised patients may be beneﬁcial.
1.Introduction
Coinfection with HBV is common in HIV-infected individu-
als because of their shared routes of transmission. Chronic
hepatitis B virus (HBV) infection aﬀects approximately
7% to 15% of HIV-infected persons worldwide [1]. The
incidenceofcomplicationsarisingfromHBV-associatedliver
disease among coinfected patients represents a signiﬁcant
challenge for both patients and clinicians. Management
of coinfection has always been challenging because of
interaction between two viruses, deciding when to initiate
the therapy, dual action of some drugs, and morbidity and
mortality associated with these diseases. We report a case of
simultaneous acute HBV and acute HIV coinfection and its
management.
2.CaseReport
A23-year-oldhomosexualmalewithoutpastmedicalhistory
presented with a 5-day history of fever, malaise, nausea,
and back pain. Social history was remarkable for multiple
sexual partners, inconsistent condom use, smoking 4-5
cigarettes/day,anddrinking6beers/weekend.Physicalexam-
inationwasnormal.Vitalsignswerenormalexceptforatem-
perature of 101
◦F. Laboratory values at admission are shown
(Table 1). By hospital day no. 5, liver function tests (LFTs)
continued to increase. After consulting with a gastroenterol-
ogist and infectious disease specialist, a decision was made
to treat both infections with tenofovir/emtricitabine and
ritonavir/lopinavir although the patient was asymptomatic.
By hospital day no. 7, when antiviral medications were
dispensed to the patient, LFTs had begun to decrease.
Laboratory values at 2 months are shown in Table 1.
At 17-month followup, pt remained stable on antiretro-
viral therapy.
3. Discussion
The prevalence of HIV/HBV coinfection varies. The geo-
graphical areas with the highest prevalence are in sub-
Saharan Africa and Asia, and the type of risk behavior with
the highest prevalence is male homosexuality [2]. There
appears to be a correlation between higher CD4+ T-cell
counts and clearance of HBV viremia during acute HBV2 Case Reports in Medicine
Table 1: Laboratory values.
Day 1 Day 5 Day 7 2 months 17 months
WBC (K/mcl) 1.7 2.6 3.8 5.7 6.2
Platelets (K/mcl) 101 101 203 208 165
Sodium (mEq/L) 131 135 134 133 135
AST (U/L) 2920 3801 1889 18 19
ALT (U/L) 3772 4951 4092 33 18
Alkaline phosphatase 82 111 119 53 64
Gamma-glutamyl transpeptidase 343 423 45 23
Albumin(g/dL) 3.4 3.3 3.7 4.0 4.3
Total bilirubin (m/dL) 0.9 2.5 4.2 1.2 1.4
INR 1.35 0.98 1.06
PT (seconds) 15.6 11.3 12.2
HBsAg + −
HBeAg + −
HBcAb IgM + +
Total HBcAb + +
HBeAb − +
HBsAb − +
Rapid HIV Ab − +
CD4 count (/cumm) 120 469 840
HIV RNA PCR (copies/mL) >10,000,000 651 <48
HBV DNA PCR (copies/mL) 22,613,715 <160
HAV Ab IgM −
HCV Ab −
HCV RNA (IU/mL) <50
infection [3]. HIV-infected individuals have an increased
incidence of nonicteric illness, higher levels of HBV DNA,
an increased rate of developing chronic hepatitis (23%),
and subsequent reactivation of hepatitis B [4]. Rates of
seroconversion are lower in HIV-infected individuals. In one
study of HBV carriers, HbeAg loss over a 5-year period was
12% in coinfected patients, compared with 49% in those
with HBV alone [5]. Most studies have shown no signiﬁcant
inﬂuenceofHBVinfectionontheprogressionofHIVdisease
[4, 5].
Thereislittleevidencetosupporttreatmentofacutehep-
atitis B infection except in severe, protracted, or fulminant
cases [6]. Lamivudine has been administered successfully to
patients who develop de novo Hepatitis B after liver trans-
plantation [7, 8]. Treatment of acute hepatitis B infection
alone in patients with underlying HIV infection is further
complicated by potential for emergence of HIV resistance
mutations because of dual action of some drugs, thereby
limiting further treatment options.
The diagnosis of Acute HIV infection is established by
documenting a high viral load in a patient with typical clin-
ical features and a negative or indeterminate HIV Antibody
test. In our patient, the Rapid HIV test used was the FDA-
approved OraQuick ADVANCE Rapid HIV-1/2 Antibody
Test from OraSure Technologies, using whole blood. It is
extremely sensitive and does not require conﬁrmation for a
negative test. The HIV viral load was determined using the
Roche Ambliprep/Cobas (R) Taqman (R) HIV-1 test kit.
The need for treatment of acute HIV infection is still
debatable. An early report showed that persons with symp-
tomaticHIVinfectionhadamorerapidlyprogressivecourse,
and the authors suggested treatment for those patients [9].
The beneﬁts of initiating early treatment of acute HIV
infection are unclear, and the long-term issues of toxicities,
resistance, quality of life, and cost remain. An additional
concern in the setting of HBV infection in HIV/HBV
coinfection would include worsening transaminitis due
to immune reconstitution or because of antiretroviral-
associated hepatotoxicity.
There is no speciﬁc guidance on how to manage patients
that may have simultaneous acute coinfection with HIV
and Hepatitis B, such as our patient [10]. For chronically
coinfected patients, guidelines recommend initiation of
antiretroviral therapy in those initiating antihepatitis B
therapy, in order to avoid developing HIV resistance to
agents that treat both viral infections. For patients with
chronic HIV infection who develop acute HBV infection,
there are no speciﬁc recommendations other than to avoid
initiating antiretroviral therapy (other than lamivudine) in
those with fulminant liver disease [11].
After much consideration and review of available evi-
dence, we decided to manage our patient with antiretroviral
therapy that treats HBV. We believe that there is suﬃcient
evidence to support treatment of acute HIV with antiretro-
viral therapy. Although our patient did not have evidence of
fulminant hepatits, the continued increase in transaminaseCase Reports in Medicine 3
levels was concerning. Treatment in our patient may have
contributed to eventual seroconversion with immunity to
HBV. It is clear that patients with chronic HIV infection are
less likely to seroconvert. The rate of clearance of HBV in
persons with acute HIV infection is unknown but likely to
be even less than those with chronic HIV.
ApreviousreportofconcurrentHBVandHIVinfections
described a case of acute HBV infection with a negative HIV
test,followedbyapositiveHIVtestseveralmonthslater[12].
To the best of our knowledge, this is the ﬁrst case report
of simultaneous acute HBV and acute HIV coinfection and
management.
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